Y-mAbs Therapeutics, Inc. Made Big Gain

Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ) shot up at $8.25, a gain of 26%. On Thu, Feb 10, 2022, YMAB:NASDAQ hit a New 2-Week Low of $6.55. The stock got featured on our News Catalysts scanner on Fri, Feb 11, 2022 at 10:19 AM in the 'BIOTECH' category. From Fri, Jan 28, 2022, the stock recorded 33.33% Up Days and 20.00% Green Days

About Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ)

Y-mAbs Therapeutics Inc is a late-stage clinical biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Products developed by the company include naxitamab for the treatment of pediatric patients with relapsed or refractory and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system.